
Reset all filters
01 2Ebixa
02 3Namenda
03 4Namenda XR
04 3Namzaric
Main Therapeutic Indication : Alzheimer Disease
Currency : USD
2017 Revenue in Millions : 453
2016 Revenue in Millions : 628
Growth (%) : -28
Main Therapeutic Indication : Neurological/Mental Disorders
Currency : USD
2018 Revenue in Millions : 71
2017 Revenue in Millions : 453
Growth (%) : -84%
Main Therapeutic Indication : Alzheimer Diseases
Currency : USD
2016 Revenue in Millions : 628
2015 Revenue in Millions : 759
Growth (%) : -17
Memantine, Donepezil Hydrochloride
Main Therapeutic Indication : Neurological/Mental Disorders
Currency : USD
2017 Revenue in Millions : 131
2016 Revenue in Millions : 58
Growth (%) : 128
Main Therapeutic Indication : Alzheimer Disease
Currency : USD
2017 Revenue in Millions : 0.1
2016 Revenue in Millions : 15
Growth (%) : -99
Memantine, Donepezil Hydrochloride
Main Therapeutic Indication : Neurological/Mental Disorders
Currency : USD
2018 Revenue in Millions : 116
2017 Revenue in Millions : 131
Growth (%) : -12%
Memantine, Donepezil Hydrochloride
Main Therapeutic Indication : Neurological/Mental Disorders
Currency : USD
2016 Revenue in Millions : 58
2015 Revenue in Millions : 11
Growth (%) : 427
Main Therapeutic Indication : Alzheimer Diseases
Currency : USD
2016 Revenue in Millions : 15
2015 Revenue in Millions : 556
Growth (%) : -97
Main Therapeutic Indication : CNS & Anesthesia
Currency : USD
2019 Revenue in Millions : 23
2018 Revenue in Millions : 71
Growth (%) : -68